SOURCE: Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc.

August 30, 2011 09:00 ET

New Distribution Agreement Signed for Germany, Switzerland, Austria and the Netherlands

SAN DIEGO, CA--(Marketwire - Aug 30, 2011) - Therapeutic Solutions International, Inc. (OTCQB: TSOI) (PINKSHEETS: TSOI), the only manufacturer of the chairside NTI Tension Suppression System ("NTI-tss") that has helped countless patients prevent debilitating migraine and tension headache pain, announced today the signing of a sales and distribution agreement with Zantomed, GmbH, a dental supply company headquartered in Duisburg, Germany.

The NTI-tss is the most effective non-drug FDA approved method of migraine prevention on the market today. The NTI-tss is a device that a dentist fits on a patient for the treatment of medically diagnosed migraine pain, as well as migraine associated tension-type headaches, by reducing their signs and symptoms through the reduction of trigeminally innervated muscular activity, and for the prevention of bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular activity.

"Distributing the NTI-tss system allows us to support a huge number of dentists in helping their patients find relief from headaches, migraine, and other head, neck, and facial pain, with an affordable and quick to use tool," said Benjamin Hatzmann, General Manager of Zantomed. "We will now work to actively promote the system in Germany, Switzerland, Austria and the Netherlands and look forward to a long and prosperous collaboration with TSI."

"This sales agreement signed with Zantomed, bringing the NTI into the markets of Germany, Austria, Switzerland and the Netherlands, is a significant milestone for TSI," stated Tim Dixon, President of Therapeutic Solutions International, Inc. "We will continue to seek new distributors in those countries of the European Union that we don't yet have agreements with, but we are very pleased to add Zantomed and these four new countries."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc. is a company that has developed, is producing and currently marketing the FDA approved NTI Tension Suppression System for the prevention of medically diagnosed migraine pain. The NTI dental device is the most cost effective, non-drug method of migraine prevention on the market today. TSI currently has strong International Patent Protection in those countries we are marketing our products into. TSI has several important websites to disseminate information and market their products. Our patient education site located at www.headacheprevention.com, and our corporate website for TSI is www.therapeuticsolutionsint.com.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

Contact Information

  • For more information please contact:

    Jens Dalsgaard
    President
    Constellation Asset Advisors, Inc
    (415) 524-8500
    info@constellationaa.com